Till startsida
University of Gothenburg
To content Read more about how we use cookies on gu.se


Morphotek is a company within the life science industry that focus on the discovery and development of monoclonal antibodies (mABs) to treat cancer, inflammation and infectious diseases.

The TAT group has recently been granted a preclinical MTA to explore the possibility to use Morphotek's flagship antibody Farletuzumab for targeted alpha therapy of Ovarian Cancer with Astatine-211

Page Manager: Emma Aneheim|Last update: 11/11/2015

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?